In a subsequent head-to-head study comparing trametinib to docetaxel after progression on platinum-doublet frontline therapy in KRAS-mutated NSCLC, progression-free survival was similar in both groups: 12 weeks in the trametinib group and 11 weeks in the docetaxel group (HR 1.14; 95% CI 0.75–1.75; p = 0.5197). Here, KRAS is linked to non-small cell lung carcinoma.